Phytochemicals targeting epidermal growth factor receptor (EGFR) for the prevention and treatment of HNSCC: A review

Medicine (Baltimore). 2023 Oct 6;102(40):e34439. doi: 10.1097/MD.0000000000034439.

Abstract

Head and neck squamous cell carcinoma (HNSCC) develops from the mucosal epithelium of the oral cavity, pharynx, and larynx, and is the most common malignancy of the head and neck, the incidence of which continues to rise. The epidermal growth factor receptor is thought to play a key role in the pathogenesis of HNSCC. Inhibition of epidermal growth factor receptor has been identified as an effective target for the treatment of HNSCC. Many phytochemicals have emerged as potential new drugs for the treatment of HNSCC. A systematic search was conducted for research articles published in PubMed, and Medline on relevant aspects. This review provides an overview of the available literature and reports highlighting the in vitro effects of phytochemicals on epidermal growth factor in various HNSCC cell models and in vivo in animal models and emphasizes the importance of epidermal growth factor as a current therapeutic target for HNSCC. Based on our review, we conclude that phytochemicals targeting the epidermal growth factor receptor are potentially effective candidates for the development of new drugs for the treatment of HNSCC. It provides an idea for further development and application of herbal medicines for cancer treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / metabolism
  • Carcinoma, Squamous Cell* / prevention & control
  • Cell Line, Tumor
  • Epidermal Growth Factor / therapeutic use
  • ErbB Receptors
  • Head and Neck Neoplasms* / drug therapy
  • Head and Neck Neoplasms* / prevention & control
  • Phytochemicals / pharmacology
  • Phytochemicals / therapeutic use
  • Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

  • ErbB Receptors
  • Epidermal Growth Factor
  • Phytochemicals